Tracleer (Bosentan) by Actelion
Digital Ulcers, Pulmonary Fibrosis,
Pulmonary Hypertension (PH), Raynaud's, Scleroderma Renal Crisis, and Skin Fibrosis
Overview
Tracleer® (bosentan) is made by Actelion Pharmaceuticals, Inc. The medication was initially developed for treatment of pulmonary hypertension, but has since proven useful in treating a variety of systemic scleroderma symptoms.
Tracleer (Bosentan) is proving useful for a variety of scleroderma symptoms, including pulmonary fibrosis, pulmonary hypertension, Raynaud's, and skin fibrosis. Bosentan is in a class of drugs called endothelin receptor antagonists by preventing an overproduction of endothelin.
Therefore, scleroderma researchers suggest that an early use of this drug should be considered for systemic scleroderma patients.
Tracleer (Bosentan) Drug Information including precautions, side effects and interactions. It may cause serious liver problems. Liver function should be monitored closely to decrease the risk of liver-related side effects. MedicineNet.
Tracleer (Bosentan) for Digital Ulcers
Tracleer is approved for the treatment of digital ulcers.
Effect of bosentan in pulmonary hypertension development in systemic sclerosis (SSc) patients with digital ulcers. We concluded that SSc patients with digital ulcers treated with bosentan seems to have less risk to develop pulmonary hypertension and to stabilize carbon monoxide diffusing capacity. PubMed, PLoS One, 2020 Dec 10;15(12):e0243651.
A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study. Bosentan therapy may indirectly influence functionality and quality of life in patients with scleroderma by reducing the burden of Raynaud's and digital ulcer-related symptoms. PubMed, Exp Ther Med, 2020 Mar;19(3):1739-1746.
Tracleer is approved for the treatment of pulmonary hypertension.
Bosentan increases myocardial perfusion and function in systemic sclerosis: a magnetic resonance imaging and Tissue-Doppler echography study. Short-term treatment with bosentan simultaneously improves myocardial perfusion and function, as evaluated by highly sensitive and quantitative methods, in patients with SSc. Whether additional remodeling effect may be observed after longterm treatment with bosentan remains to be determined. J Rheumatol.
Tracleer (Bosentan) for Pulmonary Fibrosis (PF)
Tracleer is approved for the treatment of pulmonary hypertension.
Pulmonary (lung) fibrosis, is a scarring of the lungs, and is the consequence of untreated pulmonary inflammation (alveolitis). It is often also referred to as interstitial lung disease. ISN.
Tracleer (Bosentan) for Pulmonary Hypertension (PH, PAH)
Tracleer (Bosentan) is approved for the treatment of pulmonary hypertension.
The Actelion Pathways program is a free patient support program for people on Tracleer (Bosentan). It was formerly known as Sure Steps.
Actelion Pathways. We provide help getting started on your new treatment, programs to help you pay for your medicine, and information about specialty pharmacies and mail delivery. Actelion.
Endothelial to Mesenchymal Transition (EndMT): Role in Physiology and in the Pathogenesis of Human Diseases. The identification of molecules and regulatory pathways involved in EndMT and the discovery of specific EndMT inhibitors should provide novel therapeutic approaches for various human disorders mediated by EndMT. PubMed, Physiol Rev, 2019 Apr 1;99(2):1281-1324. (Also see Macitentan (Opsumit™) and Fibroblasts)
Beneficial effects of long–term treatment with bosentan on the development of pulmonary arterial hypertension in patients with systemic sclerosis. Long–term treatment with bosentan reduces the risk of developing PAH in patients with systemic sclerosis. PubMed, J Int Med Res.
Tracleer (Bosentan) for Raynaud's
Bosentan study for Raynaud's shows positive results.
Raynaud's is an extreme spasm of blood vessels in response to cold or stress. The fingers and/or toes become white and/or blue, and may become red on re-warming. (Also see Raynaud's Treatments)
A patient-centered approach to the burden of symptoms in patients with scleroderma treated with Bosentan: A prospective single-center observational study. Bosentan therapy may indirectly influence functionality and quality of life in patients with scleroderma by reducing the burden of Raynaud's and DU-related symptoms. PubMed, Exp Ther Med, 2020 Mar;19(3):1739-1746. (Also see Raynaud's Treatments)
Bosentan for Scleroderma Renal Crisis
Clinical Trial in France
Effect of Bosentan in Scleroderma Renal Crisis (ScS-REINBO). This French clinical trial will be completed in June 2014. ClinicalTrials.gov.
Tracleer (Bosentan) for Systemic Scleroderma Skin Fibrosis
Tracleer study for systemic scleroderma skin fibrosis shows positive results.
Skin fibrosis is a process that follows chronic inflammation. Fibrotic tissue is like a scar tissue, thick, and rigid, due to an excess accumulation of protein below the skin. The diagnosis is clinical, and requires no laboratory or special testing. (Photo: Sclerodactyly, the culminating result of fibrosis affecting the hands of a systemic scleroderma patient.)
Also See
Systemic Scleroderma Symptoms (Main list; treatments are listed on each symptom page.)
Scleroderma Treatments and Clinical Trials
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:
7455 France Ave So #266
Edina, MN 55435-4702 USA